Figure 1


30000
20000
10000
0
MESF signal receptor binding
0.01
0.1
1
10
100
1000
10000
Anti-NKG2A concentration (ng/ml)

Figure 2


Predicted NKG2A occupancy following i.v. injections Q2W
NKG2A Occ (%)
100
80
60
40
20
0
0 2 4 6 8 10 12 14 16 18 20 22 24
Time after Dose (weeks)
Dose Level
0.01mg/kg
0.02mg/kg
0.03mg/kg
0.04mg/kg
0.2mg/kg
0.4mg/kg
2mg/kg
4mg/kg
10mg/kg

Figure 3A


% of max. CD107 response
100
50
0
0.01
0.1
1
10
100
1000
10000
Anti-NKG2A concentration (ng/ml)

Figure 3B


Predicted IPH2201 concentration following i.v. injections Q2W
IPH2201 Conc (µg/mL)
1000
100
10
1
0.1
0.01
0
2
4
6
8
10
12
14
16
18
20
22
24
Time after Dose (weeks)
0.01mg/kg
0.02mg/kg
0.03mg/kg
0.04mg/kg
0.2mg/kg
0.4mg/kg
2mg/kg
4mg/kg
10mg/kg

Figure 3C


Predicted IPH2201 concentration
following constant dose of 4mg/kg versus
1 loading dose of 10mg/kg then constant dose of 4mg/kg
IPH2201 Conc (µg/mL)
1000
100 µg/ml
10
0 2 4 6 8 10 12 14 16 18 20 22 24
Time after Dose (weeks)
10mg/kg then 4mg/kg
4mg/kg

Figure 4A


HLA-E expression
neg/low
high
No Target
K562 Clone F7
K562 Clone E6
%CD107+ on NKG2A- NK cells
%CD107+ on NKG2A+ NK cells
%CD137+ on NKG2A- NK cells
%CD137+ on NKG2A+ NK cells
Anti-NKG2A
0
20
40
60
80
-
+

Figure 4B


HLA-E expression
neg/low
med.
med.
H-N
FaDu
CAL-27
% CD107+ on NKG2A- NK cells
% CD107+ on NKG2A+ NK cells
% CD137+ on NKG2A- NK cells
% CD137+ on NKG2A+ NK cells
Anti-NKG2A
-
+

Figure 5


CD107
CD137
% CD107+ on NKG2A- NK cells
% CD137+ on NKG2A- NK cells
% CD107+ on NKG2A+ NK cells
% CD137+ on NKG2A+ NK cells
NKG2A+ NK only
NKG2A+ NK + Targets
NKG2A- NK only
NKG2A- NK + Targets
Anti-NKG2A 10 µg/mL
Ctx 0.001 µg/mL
Ctx 0.01 µg/mL

Figure 6A


NKG2A- NK cells vs. No target
NKG2A+ NK cells vs. No target
NKG2A- NK cells vs. K562 clone F7
NKG2A+ NK cells vs. K562 clone F7
NKG2A- NK cells vs. K562 clone E6
NKG2A+ NK cells vs. K562 clone E6
Anti-NKG2A
0 µg/mL
0.1 µg/mL
1 µg/mL
10 µg/mL
% CD107 on NK NKG2A-
% CD107 on NK NKG2A+
Cetuximab (µg/mL)
0
0.001
0.01
0.1
0.1 + 10 µg/mL hIgG4
Neg/low
HLA-E Expression
High

Figure 6B


low
HLA-E Expression
Medium
NKG2A- NK cells vs. H-N
NKG2A+ NK cells vs. H-N
NKG2A- NK cells vs. FaDu
NKG2A+ NK cells vs. FaDu
NKG2A- NK cells vs. CAL-27
NKG2A+ NK cells vs. CAL-27
% CD107 on NK NKG2A-
% CD107 on NK NKG2A+
Cetuximab (µg/mL)
0
0.001
0.01
0.1
0.1 + 10 µg/mL hIgG4
Anti-NKG2A
0 µg/mL
0.1 µg/mL
1 µg/mL
10 µg/mL